The DOI matches its OpenAlex record.
Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab
Abstract
5507 Background: The majority of head and neck cancers overexpress the epidermal growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor clinical outcome. Preclinical in vitro and in vivo model systems demonstrate radiosensitization following molecular inhibition of EGFR signaling. Promising phase I/II clinical results were achieved when radiation was combined with the EGFR blocking antibody, cetuximab, in patients with locoregionally advanced squamous cell carcinoma (SCC) of the head and neck (H&N). This phase III international trial was designed to examine the impact of combining cetuximab with high dose radiation on locoregional disease control and survival in patients with locally advanced H&N cancer. Methods: Patients with locoregionally advanced SCC of the oropharynx, hypopharynx or larynx with measurable disease were eligible to enroll. Patients were stratified by Karnofsky score 60–80 vs. 90–100, node positive vs. negative, T1–3 vs. T4, radiation fractionation regimen (once-a-day vs. twice-a-day vs. concomitant boost), and were randomized to receive either radiation alone for 6–7 weeks, or radiation plus weekly cetuximab. Following completion of treatment, patients were followed by physical examination and radiographic imaging every 4 months for 2 years, and then every 6 months up to 5 years. Results: From 04/99 to 03/02, 424 patients were randomized on this trial in the USA (61%), Europe (28%), and other countries. Median age was 57; 80% were male; 69% had KPS 90–100; 60% had oropharyngeal, 25% laryngeal, and 15% hypopharyngeal primary tumors. The two treatment arms were well balanced with regard to patient characteristics and stratification factors. The two arms were also well balanced with respect to radiation dose and fractions received, use of post-radiotherapy neck dissection, and secondary cancer therapy. Minimum and median durations of follow-up were 24 and 38 months, respectively. Median survival times, two and three-year survival rates derive from Kaplan-Meier estimates. Survival and selected safety results are as follows: The overall toxicity profile was dominated by classic known effects of high dose H&N radiation, although some additional toxicity was attributed to cetuximab. Locoregional control assessment is ongoing. Conclusions: The addition of cetuximab to high dose radiation in patients with locoregionally advanced SCC of H&N demonstrated a statistically significant prolongation in overall survival. This clinical benefit was achieved with minimal enhancement in the overall toxicity profile associated with curative-intent radiation therapy. These results corroborate the promising preclinical and earlier phase clinical results supporting the use of EGFR blockade in combination with radiation for advanced SCC of H&N. Furthermore, this combination treatment should be explored in other common epithelial malignancies demonstrating EGFR overexpression. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ImClone Systems ImClone Systems ImClone Systems ImClone Systems
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Self-citationComparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Self-citationEpidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Self-citationRepopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
Metadata
- Authors
- Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Cohen, R. B., Raben, D., Jones, C. U., Kies, M. S., Baselga, J., & Ang, K. K.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14_suppl
- Pages
- 5507-5507
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2272178001
- Cited by
- 219
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. https://app.cochat.ai/papers/10.1200/jco.2004.22.14_suppl.5507
- The paper
- Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Cohen, R. B., Raben, D., Jones, C. U., Kies, M. S., Baselga, J., & Ang, K. K. (2004). Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.22.14_suppl.5507
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.